Russian Heart Failure Journal 2011year DiUretic therapy with Effective doses of oraL diuretics: torasemide (Diuver®) and furosemide in patients with acute exacerbation of Chronic Heart Failure (DUEL–CHF)


To access this material please log in or register

Register Authorize
2011/

DiUretic therapy with Effective doses of oraL diuretics: torasemide (Diuver®) and furosemide in patients with acute exacerbation of Chronic Heart Failure (DUEL–CHF)

Mareev V. Y.1, Vygodin V. A.2, Belenkov Y. N.3
1 –Federal State Budgetary Educational Institution of Higher Professional Education “M. V. Lomonosov Moscow State University”, Leninskie Gory 1, GSP-1, Moscow 119991
2 –Federal State Budgetary Institution, “National Research Center for Preventive Medicine” of the RF Ministry of Health Care, Petroverigsky Per. 10, Bldg. 3, Moscow 101990
3 –State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: Diuver, diuretics, exacerbation, furosemide, CHF

DOI: 10.18087/rhfj.2011.1.1479

Background. More effective and safer drugs as loop diuretic torasemide is one of main factors of successful diuretic therapy. Objective. To study the efficacy and safety of non-intensive dehydration regimen with oral diuretic torasemide (Diuver®) and furosemide in patients with decompensated heart failure in a multicenter randomized comparative clinical study. Materials and methods. The study included patients aged 18 to 75 years with decompensated CHF FC II–IV. They were randomized into treatment groups: torasemide (326 patients) and furosemide (144 patients). The starting dose for torasemide was 20 mg / day, for furosemide – 80 mg / day. Adjusted doses were used. Clinical state was evaluated with SHOKS scale, visual analog scale (VAS), also electrolyte dynamics, renal function, echocardiography were analyzed, adverse events during treatment period were recorded. Results. Non-intensive therapy with oral diuretics is well tolerated, does not cause deterioration of renal function and electrolyte disorders, leads to CHF compensation without complications in most patients with CHF and lower rate of readmission. Torasemide has advantages over furosemide on the time to CHF compensation, degree of clinical improvement and achievement of complete compensation with significantly lower rate of adverse events. Torasemide therapy leads to greater decrease in heart size in all subgroups of patients, regardless of etiology and severity of CHF. Benefits of torasemide are more pronounced in the most severe subgroup of patients with congestion in the pulmonary circulation.
  1. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29 (19):2388–2442.
  2. Fonarow GC, Abraham WT, Adams K et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293 (5):572–580.
  3. Беленков Ю. Н. Б Мареев В. Ю. Принципы рационального лечения сердечной недостаточности. – М.: «Медиа Медика», 2000. – 266 с.
  4. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297 (12):1319–1331
  5. Hernandez AF. Acute Study of Clinical Effectiveness of Nesiritide Decompensated Heart Failure Trial (ASCEND-HF) – Nesiritide or placebo for improved symptoms and outcomes in acute decompensated HF. American Heart Association 2010 Scientific Sessions; November 14, 2010; Chicago, IL. Late-Breaking Clinical Trials I. Available at: http://www.medscape.com / viewarticle / 732501
  6. Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009 Apr 25;373 (9673):1429–1439.
  7. Massie BM, O’Connor CM, Metra M et al. Rolofylline, an adenosine A1‑receptor antagonist, in acute heart failure. N Engl J Med. 2010;363 (15):1419–1428.
  8. Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49 (6):675–683
  9. Felker GM, O’Connor CM, Braunwald E; Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2 (1):56–62.
  10. Felker MC & O`Connor C–Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE) Report on ACC, Atlanta, March 2010. Available at: http://www.medscape.com / viewarticle / 718675
  11. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. (COPERNICUS). N Engl J Med. 2001;344 (22):1651–1658.
  12. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  13. Fonarow GC, Adams KF Jr, Abraham WT et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293 (5):572–580.
  14. Hernandez AF, Greiner MA, Fonarow GC et al. Relationship between early physician follow-up and 30‑day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303 (17):1716–1722.
  15. Murray MD, Deer MM, Ferguson JA et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111 (7):513–520.
  16. Brater DC. Loop diuretics – translating pharmacokinetic properties into improved clinical outcomes. Eur Heart J. 2001;3 (Suppl G):G19‑G24.
  17. Gupta S, Waywell C, Gandhi N et al. The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. Eur J Heart Fail. 2010;12 (7):746–752.
  18. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41 (Suppl 3): 80–91.
  19. Patterson JH, Adams KF Jr, Applefeld MM et al. for the Torsemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994;14 (5):514–521.
  20. Uchida T, Yamanaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205 (2):145–150.
  21. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63 (3):PL45–50.
  22. Knauf H, Mutschler E, Velazquez H, Giebisch G. Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur J Clin Pharmacol. 2009;65 (5):465–472
  23. Spannheimer A, Goertz A, Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract. 1998;52 (7):467–471.
  24. Kasama S, Toyama T, Hatori T et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92 (10):1434–1440.
  25. Fassbinder W, Achhammer I, Ziegler J. Improved prognosis of patients with chronic heart failure by an optimized diuretic therapy with the new loop diuretic torasemide. J Am Col Cardiol. 1998;31 (Suppl C):Abstr. 1401.
  26. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail. 2003;5 (6):793–801.
  27. Cosin J, Diez J. Torasemide in chronic heart failure: Results of the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513.
  28. Fortuno A, Muniz P, Ravassa S et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34 (1):138–143.
  29. Veeraveedu PT, Watanabe K, Ma M et al. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol. 2008;581 (1-2):121–131.
  30. Yamato M, Sasaki T, Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384–390.
  31. Lopez B, Querejrta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43 (11):2028–2035.
  32. Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112 (25):3958–3968.
  33. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50 (8):768–777.
  34. López B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50 (9):859–867.
  35. Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoeconomic assessment of torasemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther. 1999;21 (5):854–866.
Mareev V.Y., Vygodin V.A., Belenkov Y.N. DiUretic therapy with Effective doses of oraL diuretics: torasemide (Diuver®) and furosemide in patients with acute exacerbation of Chronic Heart Failure (DUEL–CHF). Russian Heart Failure Journal. 2011;12(1):3-10.

To access this material please log in or register

Register Authorize
Ru En